Cargando…

Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy

PURPOSE: To identify characteristics of Caucasian chronic central serous chorioretinopathy (cCSC) patients without a complete resolution of subretinal fluid (SRF) after reduced-settings photodynamic therapy (PDT), or with a recurrence of SRF after PDT. METHODS: Chronic CSC patients treated with redu...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Rijssen, Thomas J., van Dijk, Elon H. C., Dijkman, Greet, Boon, Camiel J. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Retinal Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060777/ https://www.ncbi.nlm.nih.gov/pubmed/29732468 http://dx.doi.org/10.1007/s00417-018-4003-z

Ejemplares similares

Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy
por: van Rijssen, Thomas J., et al.
Publicado: (2020)

Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy
por: van Rijssen, Thomas J., et al.
Publicado: (2020)

Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3
por: Feenstra, Helena M. A., et al.
Publicado: (2022)

Fundus autofluorescence abnormalities can predict fluorescein angiography abnormalities in patients with chronic central serous chorioretinopathy
por: Mohabati, Danial, et al.
Publicado: (2023)

The spectrum of polypoidal choroidal vasculopathy in Caucasians: clinical characteristics and proposal of a classification
por: van Dijk, Elon H. C., et al.
Publicado: (2020)

Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea
por: van Dijk, Elon H. C., et al.
Publicado: (2017)

Clinical spectrum of severe chronic central serous chorioretinopathy and outcome of photodynamic therapy
por: Mohabati, Danial, et al.
Publicado: (2018)

Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy
por: van Rijssen, Thomas J., et al.
Publicado: (2018)

Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser
por: Gawęcki, Maciej, et al.
Publicado: (2017)

Subthreshold laser therapy with a standardized macular treatment pattern in chronic central serous chorioretinopathy
por: Schworm, Benedikt, et al.
Publicado: (2021)

Optical coherence tomography angiography–guided vs indocyanine green angiography–guided half-dose photodynamic therapy for acute central serous chorioretinopathy: 6-month randomized trial results
por: Li, Siying, et al.
Publicado: (2023)

Selective retina therapy (SRT) in patients with therapy refractory persistent acute central serous chorioretinopathy (CSC): 3 months functional and morphological results
por: Büttner, Maximilian, et al.
Publicado: (2020)

Long‐term follow‐up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser
por: van Rijssen, Thomas J., et al.
Publicado: (2021)

SINGLE-SESSION BILATERAL REDUCED-SETTINGS PHOTODYNAMIC THERAPY FOR BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
por: Pauleikhoff, Laurenz J.B., et al.
Publicado: (2023)

Central serous chorioretinopathy in active endogenous Cushing’s syndrome
por: Brinks, Joost, et al.
Publicado: (2021)

Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy
por: Mohabati, Danial, et al.
Publicado: (2018)

Cushing’s Syndrome and Hypothalamic–Pituitary–Adrenal Axis Hyperactivity in Chronic Central Serous Chorioretinopathy
por: van Haalen, Femke M., et al.
Publicado: (2018)

Central serous chorioretinopathy in primary hyperaldosteronism
por: van Dijk, Elon H. C., et al.
Publicado: (2016)

Estimation of current and post-treatment retinal function in chronic central serous chorioretinopathy using artificial intelligence
por: Pfau, Maximilian, et al.
Publicado: (2021)

INCREASING EVIDENCE FOR THE SAFETY OF FOVEA-INVOLVING HALF-DOSE PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
por: Feenstra, Helena M. A., et al.
Publicado: (2023)

Sex Hormones in Males and Females with Active Central Serous Chorioretinopathy
por: Brinks, Joost, et al.
Publicado: (2023)

Systemic complement activation in central serous chorioretinopathy
por: van Dijk, Elon H. C., et al.
Publicado: (2017)

Near-infrared reflectance imaging of neovascular age-related macular degeneration
por: Theelen, Thomas, et al.
Publicado: (2009)

Stress and vision-related quality of life in acute and chronic central serous chorioretinopathy
por: Kumar, Meenakshi, et al.
Publicado: (2020)

Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data
por: Subhi, Yousif, et al.
Publicado: (2021)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

Evaluation of Choroidal Layer Thickness in Central Serous Chorioretinopathy
por: Hanumunthadu, Daren, et al.
Publicado: (2019)

Exome sequencing in families with chronic central serous chorioretinopathy
por: Schellevis, Rosa L., et al.
Publicado: (2019)

Choroidal arteriovenous anastomoses: a hypothesis for the pathogenesis of central serous chorioretinopathy and other pachychoroid disease spectrum abnormalities
por: Brinks, Joost, et al.
Publicado: (2022)

Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort
por: Liu, Siyin, et al.
Publicado: (2022)

Photodynamic therapy for bullous retinal detachment: a single-center experience of case series with a 6-month follow-up study
por: Gao, Tingting, et al.
Publicado: (2018)

GENETIC RISK FACTORS IN SEVERE, NONSEVERE AND ACUTE PHENOTYPES OF CENTRAL SEROUS CHORIORETINOPATHY
por: Mohabati, Danial, et al.
Publicado: (2020)

Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach
por: van Dijk, Elon H. C., et al.
Publicado: (2020)

Photodynamic Therapy and Central Serous Chorioretinopathy
por: Siaudvytyte, Lina, et al.
Publicado: (2012)

Disease-modifying effects of ranibizumab for central retinal vein occlusion
por: Huang, Jason M., et al.
Publicado: (2021)

Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland
por: Zirpel, Johanna J., et al.
Publicado: (2021)

Clinical characteristics of patients with epiretinal membrane-Foveoschisis
por: Hetzel, Annegret, et al.
Publicado: (2022)

Long-term outcomes of intravitreal activated protein C injection for ischemic central retinal vein occlusion: an extension trial
por: Hara, Chikako, et al.
Publicado: (2021)

Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment
por: Zola, Marta, et al.
Publicado: (2020)

Effects of suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration in clinical setting
por: Matsubara, Hisashi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oj8d6ctbisc8cblvc43kqm1j2a